Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Not yet recruiting × Rare Tumour × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 112 Breast Neoplasms 81 Colorectal Neoplasms 52 Carcinoma, Hepatocellular 48 Stomach Neoplasms 43 Lung Neoplasms 40 Prostatic Neoplasms 39 Squamous Cell Carcinoma of Head and Neck 38 Triple Negative Breast Neoplasms 37 Small Cell Lung Carcinoma 37 Uterine Cervical Neoplasms 32 Rectal Neoplasms 32 Recurrence 27 Pancreatic Neoplasms 27 Leukemia, Myeloid, Acute 27 Neoplasms 26 Neoplasm Metastasis 25 Esophageal Squamous Cell Carcinoma 23 Ovarian Neoplasms 21 Brain Neoplasms 21 Nasopharyngeal Carcinoma 19 Esophageal Neoplasms 19 Multiple Myeloma 18 Glioblastoma 16 Colonic Neoplasms 16 Carcinoma, Renal Cell 16 Biliary Tract Neoplasms 16 Lymphoma, Large B-Cell, Diffuse 15 Endometrial Neoplasms 15 Head and Neck Neoplasms 14

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡